Allogeneic cell therapy: From bench to clinic

Allogeneic cell therapies offer off-the-shelf solutions that can benefit multiple patients from a single donor source. These therapies present several advantages over autologous approaches, including immediate availability, reduced manufacturing costs, and the potential for standardized and scalable production.

Our latest InFocus feature, developed in collaboration with RegMedNet, explores the critical considerations, emerging opportunities, and manufacturing challenges in the development of allogeneic cell therapies. This comprehensive resource provides insights into GMP compliance, scalability strategies, and regulatory requirements that are essential for successful translation from the bench to the clinic.

Infographic

Download our infographic that compares autologous and allogeneic cell therapies, highlighting different cell types used in allogeneic therapies. The infographic outlines the pros and cons of cryopreservation strategies. It also provides a clear overview of the manufacturing challenges and advantages of allogeneic cell therapies.

Expert interview

In an interview with RegMedNet, three of our experts share their expertise on establishing GMP-compliant manufacturing frameworks for scalable allogeneic cell therapies. Dr. Iris Bischoff-Kont (Product Manager Cells & Media), Dr. Lisa Hamelmann (Product Manager Cells & Media), and Dr. Lucía Cespón (GMP Business Unit Lead) discuss strategies for successful development of allogeneic cell therapy.

What you'll learn from the interview:

• Emerging allogeneic cell types showing promise for clinical applications, including macrophages, endothelial cells, and fibroblasts
• Considerations for maintaining cell quality in GMP environments, including cryopreservation strategies
• Scalable production strategies that maintain quality and consistency throughout the manufacturing process
• The importance of early regulatory engagement and proper raw material selection for smooth bench-to-clinic transition
• Emerging trends in multi-modal therapies combining allogeneic cells with gene editing, biomaterials, and biologics
• Best practices for transitioning from research-grade to clinical-grade production while ensuring GMP compliance

This interview was made in collaboration with RegMedNet